{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T14:36:53Z","timestamp":1723646213742},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,8,2]],"date-time":"2015-08-02T00:00:00Z","timestamp":1438473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2015,10]]},"abstract":"ABSTRACT<\/jats:title>There is wide variability in prescribing of antiplatelet regimens following transcatheter aortic valve implantation (TAVI<\/jats:styled-content>). The objective of this review was to evaluate published and unpublished reports regarding the efficacy and safety of dual antiplatelet therapy (DAPT<\/jats:styled-content>) compared with a single antiplatelet agent in patients undergoing TAVI<\/jats:styled-content>. We searched MEDLINE<\/jats:styled-content>, CENTRAL<\/jats:styled-content>, Embase, and unpublished sources of literature from inception to December 2014 using terms synonymous with TAVI<\/jats:styled-content> and DAPT<\/jats:styled-content>. We included randomized controlled trials (RCTs<\/jats:styled-content>) and cohort or case\u2010control studies that compared DAPT<\/jats:styled-content> with a single antiplatelet agent post\u2010TAVI<\/jats:styled-content>. Four articles met the inclusion criteria (2 RCTs<\/jats:styled-content>, 2 cohort studies), of which all were deemed to be at high risk of bias, for a total of 662 patients. Compared with a single antiplatelet agent, DAPT<\/jats:styled-content> did not significantly reduce all\u2010cause mortality (risk ratio: 1.22, 95% confidence interval: 0.72\u20102.09, I2<\/jats:sup><\/jats:styled-content><\/jats:italic> = 0%). Due to selective outcome reporting and variable follow\u2010up, other outcomes of interest could not be meta\u2010analyzed; however, evaluation of individual studies demonstrated no significant reduction in thrombotic events with DAPT<\/jats:styled-content> and a similar or higher risk of bleeding. Current evidence, though limited by low methodological quality, suggests a lack of benefit and potential harm with DAPT<\/jats:styled-content> compared with a single antiplatelet agent in patients post\u2010TAVI<\/jats:styled-content>. Therefore, clinicians should evaluate the use of DAPT<\/jats:styled-content> in patients post\u2010TAVI<\/jats:styled-content> on a case\u2010by\u2010case basis until more robust evidence is available to guide practice.<\/jats:p>","DOI":"10.1002\/clc.22426","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T04:19:33Z","timestamp":1438575573000},"page":"629-634","source":"Crossref","is-referenced-by-count":5,"title":["Single vs Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation: A Systematic Review"],"prefix":"10.1002","volume":"38","author":[{"given":"Ricky D.","family":"Turgeon","sequence":"first","affiliation":[{"name":"Doctor of Pharmacy Student, Faculty of Pharmaceutical Sciences University of British Columbia Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arden R.","family":"Barry","sequence":"additional","affiliation":[{"name":"Clinical Academic Colleague, Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta, and Clinical Pharmacist and Practice Leader, Pharmacy Services, Mazankowski Alberta Heart Institute, Alberta Health Services Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69208-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.015"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60211-7"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202277"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200384"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400590"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-013-0496-6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306118.98"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_6_11_1","unstructured":"World Health Organization.International Clinical Trials Registry Platform.http:\/\/www.who.int\/ictrp\/en\/. Accessed September 23 2014."},{"key":"e_1_2_6_12_1","unstructured":"US National Institutes of Health.ClinicalTrials.gov.https:\/\/www.clinicaltrials.gov. Accessed September 23 2014."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_14_1","unstructured":"WellsG SheaB O'Connell D et al;Ottawa Hospital Research Institute.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses.http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed September 18 2014."},{"key":"e_1_2_6_15_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2011"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.12.005"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.07.049"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.04.170"},{"key":"e_1_2_6_19_1","first-page":"544","article-title":"Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation\u2014comparison of regimes","volume":"25","author":"Poliacikova P","year":"2013","journal-title":"J Invasive Cardiol."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.09.033"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.04.015"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2305"},{"key":"e_1_2_6_23_1","first-page":"e521","article-title":"2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [published corrections appear in Circulation. 2014;129:e651 and Circulation. 2014;130:e120]","volume":"129","author":"Nishumura RA","year":"2014","journal-title":"Circulation"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.022"},{"key":"e_1_2_6_25_1","unstructured":"Aspirin versus Aspirin\u2009+\u2009Clopidogrel Following Transcatheter Aortic Valve Implantation: the ARTE Trial.http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01559298. Accessed September 22 2014."}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22426","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:50:26Z","timestamp":1696337426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,2]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/clc.22426"],"URL":"https:\/\/doi.org\/10.1002\/clc.22426","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,2]]}}}